Articles tagged with: Maintenance Therapy
Press Releases»
- Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis
- Independent Data Monitoring Committee recommends unblinding the study results
- Based on the data, Janssen plans to discuss the potential for a regulatory submission with health authorities
Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the second part of the Phase 3 CASSIOPEIA (MMY3006) study of daratumumab monotherapy as maintenance treatment versus observation (no treatment) for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant (ASCT). The second part of the study, which is being conducted by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and …
Press Releases»
- Results Demonstrated Statistically Significant Improvement in Progression-Free Survival
- Data to be Submitted for Presentation at an Upcoming Medical Meeting
Cambridge, MA and Osaka, Japan (Press Release) – Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines …
Opinion»

July 22 marked the third anniversary of my autologous (own) stem cell transplant. Honestly, although the treatment went well, when I was sent home, three-years in the future seemed like a very long time away. I wouldn't have been surprised if a relapse had arrived before this day.
Today, however, I'm still enjoying a complete response and relatively good health with remarkably few side effects. My perspective on the future also is much brighter, and three more years of good health doesn't seem like a stretch anymore.
Much of my current …
News»

A new study by U.S. researchers provides useful insights into the outcomes newly diagnosed multiple myeloma patients can expect from a common sequence of initial treatments.
Drawing on data for more than 240 patients treated between 2010 and 2017, the authors of the new study investigate treatment responses and survival outcomes for newly diagnosed myeloma patients who underwent initial treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone, followed soon thereafter with an autologous (own) stem cell transplant.
More than two thirds of the patients in the study also underwent either maintenance or …
Opinion»

As I enter my third year of maintenance therapy after experiencing very little change in my health the past couple years, I sometimes feel as though I’m just “treading water.”
While it's often considered derogatory to say that someone is treading water, being able to swim in that way is actually a very important safety skill. A swimmer isn’t going to make any forward progress treading water, but they’re going to keep their head above water (i.e., not drown) long enough to catch their breath so they can continue a longer …
Press Releases»

Cambridge, MA and Osaka, Japan (Press Release) – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral NINLARO® (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival (PFS) versus placebo. The trial evaluated the effect of NINLARO as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT). Takeda plans to submit data from the trial to regulatory agencies around the world. NINLARO …
Opinion»

Several months after I had my stem cell transplant, my doctor suggested that it would be a good idea to begin maintenance treatment with Revlimid (lenalidomide). He believed that maintenance was likely to lead to longer progression-free survival. I remember him saying that, in his experience, maintenance therapy often put the myeloma into hibernation. That sounded good to me – long-term hibernation, I hope.
He also explained to my husband Graham and me that he thought that the maintenance therapy might lead to longer overall survival. At the same time, he said that …